NZ574046A - Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration - Google Patents
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degenerationInfo
- Publication number
- NZ574046A NZ574046A NZ574046A NZ57404607A NZ574046A NZ 574046 A NZ574046 A NZ 574046A NZ 574046 A NZ574046 A NZ 574046A NZ 57404607 A NZ57404607 A NZ 57404607A NZ 574046 A NZ574046 A NZ 574046A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- age
- cfhr
- macular degeneration
- related macular
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract 4
- 208000002780 macular degeneration Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000019553 vascular disease Diseases 0.000 title abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010002329 Aneurysm Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 210000003917 human chromosome Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83101806P | 2006-07-13 | 2006-07-13 | |
| US84007306P | 2006-08-23 | 2006-08-23 | |
| PCT/US2007/073514 WO2008008986A2 (en) | 2006-07-13 | 2007-07-13 | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ574046A true NZ574046A (en) | 2012-09-28 |
Family
ID=38924245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ574046A NZ574046A (en) | 2006-07-13 | 2007-07-13 | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7867727B2 (https=) |
| EP (3) | EP2479284B1 (https=) |
| JP (1) | JP5431151B2 (https=) |
| AT (1) | ATE551350T1 (https=) |
| AU (1) | AU2007272335B2 (https=) |
| CA (1) | CA2659392A1 (https=) |
| DK (1) | DK2447275T3 (https=) |
| IL (1) | IL196319A0 (https=) |
| NZ (1) | NZ574046A (https=) |
| SG (1) | SG173371A1 (https=) |
| WO (1) | WO2008008986A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2357254A1 (en) * | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| US20080146501A1 (en) * | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| AU2007277125B2 (en) * | 2006-07-26 | 2013-08-01 | Yale University | Diagnosis and treatment of age related macular degeneration |
| EP2217720A4 (en) * | 2007-11-01 | 2010-12-08 | Univ Iowa Res Found | RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII |
| US20090186370A1 (en) * | 2008-01-18 | 2009-07-23 | Ogle Matthew F | Diagnostic biomarkers for vascular aneurysm |
| DE102008049136B4 (de) * | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| JP2012533562A (ja) * | 2009-07-16 | 2012-12-27 | グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド | 治療法 |
| US20120190578A1 (en) * | 2009-08-06 | 2012-07-26 | Washington University | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes |
| EP2478377A2 (de) * | 2009-09-14 | 2012-07-25 | Mosaiques Diagnostics And Therapeutics AG | Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen |
| JP5706612B2 (ja) * | 2009-12-28 | 2015-04-22 | 学校法人 埼玉医科大学 | 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット |
| US20120202708A1 (en) * | 2010-10-14 | 2012-08-09 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| US9598733B2 (en) * | 2011-02-17 | 2017-03-21 | The Trustees Of Columbia University In The City Of New York | Methods for identifying subjects with a genetic risk for developing IgA nephropathy |
| CA2834676A1 (en) * | 2011-04-29 | 2012-11-01 | University Of Utah Research Foundation | Methods of predicting the development of complement-mediated disease |
| JP2013064616A (ja) * | 2011-09-15 | 2013-04-11 | Osaka Univ | 高度動脈硬化を発症している可能性を検出する方法およびその利用 |
| WO2013150132A2 (de) * | 2012-04-05 | 2013-10-10 | Mosaiques Diagnostics And Therapeutics Ag | Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| EP2962106A1 (en) * | 2013-02-26 | 2016-01-06 | Roche Diagnostics GmbH | Agents, kits and methods for complement factor h-related protein 1 detection |
| US10202647B2 (en) | 2013-04-12 | 2019-02-12 | The Trustees Of Columbia University In The City Of New York | Mutations in DSTYK cause dominant urinary tract malformations |
| WO2014194213A1 (en) * | 2013-05-30 | 2014-12-04 | University Of Iowa Research Foundation | Specific complement proteins and efficacy of antibody therapy |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| JP7199966B2 (ja) | 2015-12-23 | 2023-01-06 | ソルボンヌ ウニベルシテ | ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用 |
| CA3023802C (en) | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| EP3791180A1 (en) * | 2018-05-10 | 2021-03-17 | The University Of Manchester | Methods for assessing macular degeneration |
| EP3824095A4 (en) | 2018-07-20 | 2022-04-20 | University of Utah Research Foundation | GENE THERAPY FOR MACULATE GENERATION |
| DE102018120016B4 (de) | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
| WO2020180147A2 (ko) * | 2019-03-07 | 2020-09-10 | (주)레티마크 | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 |
| WO2020210724A1 (en) | 2019-04-10 | 2020-10-15 | University Of Utah Research Foundation | Htra1 modulation for treatment of amd |
| CA3158517A1 (en) * | 2019-10-22 | 2021-04-29 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders |
| WO2022058447A1 (en) * | 2020-09-16 | 2022-03-24 | The University Of Manchester | Complementome assay |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US5037746A (en) | 1986-12-03 | 1991-08-06 | University Patents, Inc. | RNA ribozyme polymerases, and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| JP2897959B2 (ja) | 1988-05-20 | 1999-05-31 | エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト | 固定化された配列特異的プローブ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| EP1413587A2 (en) | 1991-05-03 | 2004-04-28 | Washington University | Modified complement system regulator |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| EP0681482B1 (en) | 1993-01-22 | 2005-12-07 | University Research Corporation | Localization of therapeutic agents |
| US5667969A (en) | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| NZ507093A (en) | 1998-04-08 | 2003-08-29 | Commw Scient Ind Res Org | Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| AU3704500A (en) | 1999-02-19 | 2001-01-22 | University Of Iowa Research Foundation, The | Diagnostics and therapeutics for arterial wall disruptive disorders |
| US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| AU2001261103B2 (en) | 2000-04-29 | 2007-08-23 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| US6632606B1 (en) | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
| WO2003016470A2 (en) | 2001-08-10 | 2003-02-27 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
| CN102618644A (zh) * | 2004-11-18 | 2012-08-01 | 耶鲁大学 | 治疗眼病的方法和组合物 |
| EP2357254A1 (en) | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| EP2570491A1 (en) | 2005-06-08 | 2013-03-20 | University of Pittsburgh of the Commonwealth System of Higher Education | Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26 |
| KR20080065657A (ko) | 2005-10-11 | 2008-07-14 | 예일 유니버시티 | 황반 변성 관련 유전자 |
| US20080255000A1 (en) | 2005-11-02 | 2008-10-16 | Dogulu Cigdem F | Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd) |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US20080146501A1 (en) | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| GB0611606D0 (en) * | 2006-06-13 | 2006-07-19 | Univ Belfast | Protection against and treatment of age related macular degeneration |
-
2007
- 2007-07-13 JP JP2009519713A patent/JP5431151B2/ja active Active
- 2007-07-13 SG SG2011050705A patent/SG173371A1/en unknown
- 2007-07-13 AT AT07812932T patent/ATE551350T1/de active
- 2007-07-13 EP EP12152172.8A patent/EP2479284B1/en not_active Not-in-force
- 2007-07-13 EP EP07812932A patent/EP2046807B1/en active Active
- 2007-07-13 AU AU2007272335A patent/AU2007272335B2/en not_active Ceased
- 2007-07-13 CA CA002659392A patent/CA2659392A1/en not_active Abandoned
- 2007-07-13 NZ NZ574046A patent/NZ574046A/xx not_active IP Right Cessation
- 2007-07-13 WO PCT/US2007/073514 patent/WO2008008986A2/en not_active Ceased
- 2007-07-13 EP EP12152177.7A patent/EP2447275B1/en active Active
- 2007-07-13 DK DK12152177.7T patent/DK2447275T3/en active
- 2007-08-20 US US11/894,667 patent/US7867727B2/en not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196319A patent/IL196319A0/en unknown
-
2010
- 2010-11-24 US US12/954,425 patent/US20120040884A1/en not_active Abandoned
-
2014
- 2014-05-15 US US14/279,235 patent/US20150050646A1/en not_active Abandoned
-
2018
- 2018-03-05 US US15/912,379 patent/US20180371547A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2046807A4 (en) | 2009-10-28 |
| HK1126223A1 (en) | 2009-08-28 |
| EP2479284B1 (en) | 2017-09-20 |
| EP2046807A2 (en) | 2009-04-15 |
| IL196319A0 (en) | 2009-09-22 |
| JP2009544280A (ja) | 2009-12-17 |
| CA2659392A1 (en) | 2008-01-17 |
| EP2046807B1 (en) | 2012-03-28 |
| US20080152659A1 (en) | 2008-06-26 |
| EP2479284A2 (en) | 2012-07-25 |
| US7867727B2 (en) | 2011-01-11 |
| AU2007272335A1 (en) | 2008-01-17 |
| US20120040884A1 (en) | 2012-02-16 |
| EP2447275B1 (en) | 2015-04-01 |
| DK2447275T3 (en) | 2015-06-29 |
| EP2479284A3 (en) | 2012-08-08 |
| US20180371547A1 (en) | 2018-12-27 |
| WO2008008986A2 (en) | 2008-01-17 |
| SG173371A1 (en) | 2011-08-29 |
| AU2007272335B2 (en) | 2014-03-27 |
| ATE551350T1 (de) | 2012-04-15 |
| US20150050646A1 (en) | 2015-02-19 |
| WO2008008986A3 (en) | 2008-10-23 |
| EP2447275A1 (en) | 2012-05-02 |
| HK1168360A1 (en) | 2012-12-28 |
| JP5431151B2 (ja) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ574046A (en) | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration | |
| WO2008052798A3 (en) | Fgfr4 promotes cancer cell resistance in response to chemotherapeutic drugs | |
| WO2006083533A3 (en) | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders | |
| PH12013500118A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| Gregson et al. | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date | |
| WO2008027912A3 (en) | Prediction of an agent's or agents' activity across different cells and tissue types | |
| NZ595305A (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
| WO2006044775A3 (en) | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | |
| NO20084488L (no) | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | |
| WO2008074329A3 (en) | Modulation of activity of proneurotrophins | |
| WO2008137762A3 (en) | Methods of diagnosis and treatment of crohn's disease | |
| WO2003013537A3 (en) | Irinotecan for treatment of cancer | |
| WO2006031980A3 (en) | Treatment for cancer-related fatigue | |
| GB0124145D0 (en) | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease | |
| Perche et al. | Combined deletion of two Condensin II system genes (NCAPG2 and MCPH1) in a case of severe microcephaly and mental deficiency | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| Boelman et al. | Identical ATP1A3 mutation causes alternating hemiplegia of childhood and rapid-onset dystonia parkinsonism phenotypes | |
| MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
| TW200731984A (en) | C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H | |
| WO2004006856A3 (en) | Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression | |
| Allikmets et al. | Geographic atrophy in age-related macular degeneration and TLR3. | |
| TW200628473A (en) | Novel heterocycles | |
| WO2008039409A8 (en) | Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases | |
| WO2010102160A3 (en) | Diagnostic method using palb2 | |
| WO2007084734A3 (en) | Method to determine and biomarker for treatment efficacy with ssri, snri, and sari antidepressants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 JUL 2014 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS Effective date: 20130218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 JUL 2017 BY COMPUTER PACKAGES INC Effective date: 20140729 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUL 2018 BY COMPUTER PACKAGES INC Effective date: 20170718 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUL 2019 BY COMPUTER PACKAGES INC Effective date: 20180619 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUL 2020 BY COMPUTER PACKAGES INC Effective date: 20190618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUL 2021 BY COMPUTER PACKAGES INC Effective date: 20200618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUL 2022 BY COMPUTER PACKAGES INC Effective date: 20210617 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JUL 2023 BY COMPUTER PACKAGES INC Effective date: 20220618 |
|
| LAPS | Patent lapsed |